Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cynthia Miller

Nurse Practitioner, Family Murfreesboro, TN Nurse Practitioner

NPI 1497790992 CMS profile 10813626

745 S Church St Ste 303, Murfreesboro, TN 37130

Open in the dashboard

General payments

$383,602

1,002 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cynthia Miller of Murfreesboro, TN is reported in the CMS Open Payments database as having received $383,602 across 1,002 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,819 178
2024 General $51,465 142
2023 General $137,220 310
2022 General $75,956 201
2021 General $58,141 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cynthia Miller
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Cynthia Miller were reported at $60,819. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Cynthia Miller Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $58,141 $124 $35–$379 $132
2022 $75,956 $141 $44–$430 $149
2023 $137,220 $154 $49–$476 $160
2024 $51,465 $165 $51–$504 $164
2025 $60,819 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $305,003 630 payments
  2. ITI, Inc. $36,830 119 payments
  3. Vanda Pharmaceuticals Inc. $33,063 76 payments
  4. Allergan Inc. $5,699 9 payments
  5. Alkermes, Inc. $572 31 payments
  6. Axsome Therapeutics, Inc. $460 17 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $305 19 payments
  8. Otsuka America Pharmaceutical, Inc. $281 15 payments
  9. Lundbeck LLC $268 15 payments
  10. Teva Pharmaceuticals USA, Inc. $236 13 payments
  11. Other $884 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $328,770 201 payments
  2. Travel and Lodging $38,448 244 payments
  3. Food and Beverage $12,501 554 payments
  4. Consulting Fee $3,875 2 payments
  5. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $300,739 607 payments
  2. CAPLYTA Psychiatry $36,163 78 payments
  3. FANAPT $33,063 76 payments
  4. VRAYLAR Neuroscience $9,958 31 payments
  5. CAPLYTA Psychiatry $666 41 payments
  6. Auvelity $460 17 payments
  7. LYBALVI Cns $454 24 payments
  8. LYBALVI Cns $376 18 payments
  9. LYBALVI Cns $346 16 payments
  10. LYBALVI Cns $346 16 payments
  11. Other $2,594 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

300

Median for Nurse Practitioner: 389

Drug cost

$22,871

Median for Nurse Practitioner: $21,885

Branded share of claims

28%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 20 $10,075
Lurasidone Hcl Generic 11 $5,295
Bupropion Xl Bupropion Hcl Brand 53 $2,061
Vilazodone Hcl Generic 11 $1,700
Aripiprazole Generic 17 $1,671
Fluoxetine Hcl Generic 19 $453
Quetiapine Fumarate Generic 38 $363
Risperidone Generic 11 $301
Trazodone Hcl Generic 37 $224
Eszopiclone Generic 11 $220

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$16,143

Medicare's payments for the services billed

Medicare patients

27

Average age 68

Services billed

315

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 67%
Arthritis 48%
Diabetes 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$31,673 — —
FANAPT
$19,005 — —
CAPLYTA
$224 — —
SPRAVATO
$100 — —
REXULTI
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

1,002 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record